Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure

Circulation

Volumn 98, Issue 21, 1998, Pages 2262-2268

  Sütsch, Gabor ^a   Kiowski, Wolfgang ^a   Yan, Xiao Wei ^a   Hunziker, Patrick ^b   Christen, Stefan ^b   Strobel, Werner ^a   Kim, Jong Hun ^c   Rickenbacher, Peter ^a   Bertel, Osmund ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c University Hospital ^*

Author keywords

Endothelin; Heart failure; Hemodynamics; Hormones

Indexed keywords

ANGIOTENSIN; BOSENTAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; NORADRENALIN; RENIN;

ADULT; AGED; ARTICLE; CAPILLARY PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HEART FAILURE; HEART OUTPUT; HEART RATE; HEART RIGHT ATRIUM PRESSURE; HEMODYNAMICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOTENSION; LUNG ARTERY PRESSURE; MALE; MEAN ARTERIAL PRESSURE; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; VASCULAR RESISTANCE; VERTIGO;

EID: 0032564374     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.21.2262     Document Type: Article

References (26)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1989;332:411-415.
2. Wei CM, Lerman A, Rodeheffer RJ, McGregor CG, Brandt RR, Wright S, Heublein DM, Kao PC, Edwards WD, Burnett JC. Endothelin in human congestive heart failure. Circulation. 1994;89:1580-1586.
3. Kiowski W, Sütsch G, Hunziker P, Müller P, Kim J, Oechslin E, Schmitt R, Jones R, Bertel O. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 1995;346:732-736.
4. Pacher R, Stanek B, Hülsmann M, Koller-Strametz J, Berger R, Schuller M, Hartter E, Ogris E, Frey B, Heinz G, Maurer G. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol. 1996;27:633-641.
5. Krum H, Goldsmith R, Wilshire CM, Miller M, Packer M. Role of endothelin in the exercise intolerance of chronic heart failure. Am J Cardiol. 1995;75:1282-1283.
6. Clozel M, Breu V, Gray GA, Kalina B, Löffler BM, Burri K, Cassal JM, Hirth G, Müller M, Neidhart W, Ramuz H. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther. 1994;270:228-235.
7. Teerlink JR, Löffler BM, Hess P, Maire JP, Clozel M, Clozel JP. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure: acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). Circulation. 1994;90:2510-2518.
8. Löffler BM, Maire JP. Radioimmunological determination of endothelin peptides in human plasma: a methodological approach. Endothelium. 1994;1:273-286.
9. Mefford IN. Application of high performance liquid chromatography with electrochemical detection to neurochemical analysis: measurement of catecholamines, serotonin and metabolites in rat brain. J Neurosci Methods. 1981;3:207-224.
10. Kappelgaard AM, Nielsen MD, Giese J. Measurement for angiotensin II in human plasma: technical modifications and practical experience. Clin Chim Acta. 1976;67:299-306.
11. A receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation. 1996;94:2131-2137.
12. Sülsch G, Bertel O, Kiowski W. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans. Cardiovasc Drugs Ther. 1996;10:717-725.
13. Levine TB, Levine AB, Goldberg D, Narins B, Goldstein S, Lesch M. Impact of medical therapy on pulmonary hypertension in patients with congestive heart failure awaiting cardiac transplantation. Am J Cardiol. 1996;78:440-443.
14. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 1996;384:353-355.
15. Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, Compagnon P, Macé B, Comoy E, Letac B, Thuillez C. Role of endogenous endothelin in chronic heart failure: effect of a long-term treatment with an endothelin antagonist on survival, hemodynamics and cardiac remodeling. Circulation. 1997;96:1976-1982.
16. Pfeffer JM, Pfeffer MA, Braunwald E. Hemodynamic benefits and prolonged survival with long-term captopril therapy in rats with myocardial infarction and heart failure. Circulation. 1987;75(suppl I):I-149-I-155.
17. Ellenbogen KA, Mohanty PK, Szentpetery S, Thames MD. Arterial baroreflex abnormalities in heart failure: reversal after orthotopic cardiac transplantation. Circulation. 1989;79:51-58.
18. B receptors mediate contraction to endothelin-1 in human blood vessels. Circulation. I994;89:1203-1208.
19. Schricker K, Scholz H, Hamann M, Clozel M, Kramer BK, Kurtz A. Role of endogenous endothelins in the renin system of normal and two-kidney, one clip rats. Hypertension. 1995;25:1025-1029.
20. Löftier BM, Roux S, Kalina B, Clozel M, Clozel JP. Influence of congestive heart failure on endothelin levels and receptors in rabbits. J Mol Cell Cardiol. 1993;25:407-416.
21. Spinale FG, Walker JD, Mukherjee R, Iannini JP, Keever AT, Gallagher KP. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits: beneficial effects on left ventricular and myocyte function. Circulation. 1997;95:1918-1929.
22. Krum H, Wilshire CM, Sackner BJ, Goldsmith R, Medina N, Yushak M, Miller M, Packer M. Plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure. Am Heart J. 1996;131:337-341.
23. Cody R, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85:504-509.
24. Takayanagi R, Kitazumi K, Takasaki C, Ohnaka K, Aimoto S, Tasaka K, Ohashi M, Nawata H. Presence of non-selective type of endothelin receptor on vascular endothelium and its linkage to vasodilation. FEBS Lett. 1991;282:103-106.
25. Boulanger C, Lüscher TF. Release of endothelin from the porcine aorta: inhibition by endothelium-derived nitric oxide. J Clin Invest. 1990;85:587-590.
26. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med. 1998;338:784-790.